WO2012036433A3 - miRNA를 타겟으로 한 신경퇴행성 질환 치료 - Google Patents

miRNA를 타겟으로 한 신경퇴행성 질환 치료 Download PDF

Info

Publication number
WO2012036433A3
WO2012036433A3 PCT/KR2011/006718 KR2011006718W WO2012036433A3 WO 2012036433 A3 WO2012036433 A3 WO 2012036433A3 KR 2011006718 W KR2011006718 W KR 2011006718W WO 2012036433 A3 WO2012036433 A3 WO 2012036433A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative diseases
present
mir
treatment
targeting
Prior art date
Application number
PCT/KR2011/006718
Other languages
English (en)
French (fr)
Other versions
WO2012036433A2 (ko
Inventor
노재규
이상건
김만호
주건
정근화
이순태
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Priority to JP2013529052A priority Critical patent/JP5710001B2/ja
Priority to EP11825393.9A priority patent/EP2617433B1/en
Priority to CN201180053509.7A priority patent/CN103189069B/zh
Priority to US13/822,641 priority patent/US9301969B2/en
Publication of WO2012036433A2 publication Critical patent/WO2012036433A2/ko
Publication of WO2012036433A3 publication Critical patent/WO2012036433A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 특정 miRNA를 타겟으로 한 신경퇴행성 질환의 예방 또는 치료용 약제학적 조성물에 관한 것이다. 또한, 본 발명은 신경퇴행성 질환의 진단용 키트에 관한 것이다. 본 발명에서 발굴된 miR-206 타겟은 알쯔하이머 동물 모델 및 인간 뇌 시료에서 공통적으로 고발현 된 것으로서 실험적 오차(artifact errors) 없이 선택된 실질적인 치료 타겟이다. miR-206의 억제제로서 본 발명의 안티센스 올리고뉴클레오타이드는 miRNA를 타겟으로 한 신경퇴행성 질환 치료에 있어서 최초로 성공적인 결과를 제시한다. 본 발명의 안티센스 올리고뉴클레오타이드는 miR-206의 기능을 억제하여 BDNF 및 IGF-1의 레벨을 크게 증가시키며 시냅스 재생을 증가시켜 결국 신경퇴행성 질환 특히 알쯔하이머 질환을 치료한다.
PCT/KR2011/006718 2010-09-13 2011-09-09 miRNA를 타겟으로 한 신경퇴행성 질환 치료 WO2012036433A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2013529052A JP5710001B2 (ja) 2010-09-13 2011-09-09 ｍｉＲＮＡをターゲットとした神経変性疾患の治療
EP11825393.9A EP2617433B1 (en) 2010-09-13 2011-09-09 Treatment of alzheimer's disease by targeting mirna
CN201180053509.7A CN103189069B (zh) 2010-09-13 2011-09-09 以miRNA为靶的神经退行性疾病的治疗
US13/822,641 US9301969B2 (en) 2010-09-13 2011-09-09 Treatment of neurodegenerative diseases by targeting miRNA

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0089651 2010-09-13
KR1020100089651A KR101235256B1 (ko) 2010-09-13 2010-09-13 ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료

Publications (2)

Publication Number Publication Date
WO2012036433A2 WO2012036433A2 (ko) 2012-03-22
WO2012036433A3 true WO2012036433A3 (ko) 2012-06-28

Family

ID=45832075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/006718 WO2012036433A2 (ko) 2010-09-13 2011-09-09 miRNA를 타겟으로 한 신경퇴행성 질환 치료

Country Status (6)

Country Link
US (1) US9301969B2 (ko)
EP (1) EP2617433B1 (ko)
JP (1) JP5710001B2 (ko)
KR (1) KR101235256B1 (ko)
CN (1) CN103189069B (ko)
WO (1) WO2012036433A2 (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP3702460A1 (en) 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
US20140259192A1 (en) * 2011-07-12 2014-09-11 Sanofi Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene
AU2013262702A1 (en) * 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating BDNF expression
US20150152410A1 (en) 2012-05-16 2015-06-04 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EP2895606A4 (en) * 2012-09-17 2016-07-06 Res Inst Nationwide Childrens Hospital COMPOSITIONS AND METHOD FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS (ALS)
US10011873B2 (en) 2012-11-16 2018-07-03 Universitat Des Saarlandes Diagnostic miRNA markers for Parkinson disease
EP2733220B1 (en) 2012-11-16 2017-10-18 Siemens Aktiengesellschaft Novel miRNA as a diagnostic marker for Alzheimer's Disease
EP2733219B1 (en) 2012-11-16 2017-09-20 Siemens Aktiengesellschaft Diagnostic miRNA markers for Alzheimer
KR101566586B1 (ko) * 2013-08-21 2015-11-16 서울대학교산학협력단 miRNA를 표적으로 하는 뇌전증 또는 발작 관련 질환의 예방 또는 치료용 약학 조성물 및 방법
WO2015179909A1 (en) * 2014-05-26 2015-12-03 The University Of Melbourne Mirna biomarkers of alzheimer's disease
CN104278100B (zh) * 2014-10-16 2016-02-10 上海交通大学医学院附属仁济医院 miRNA-188作为标记分子在制备诊断试剂中的用途
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1)
KR101734645B1 (ko) * 2015-05-18 2017-05-11 (주)에이엔티랩스 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법
US10272093B2 (en) * 2015-06-08 2019-04-30 Regents Of The University Of California Use of H3K9me3 modulation for enhancing cognitive function
ITUB20155765A1 (it) * 2015-11-20 2017-05-20 Braindtech S R L Metodi per diagnosi, prognosi e monitoraggio terapeutico di patologie neurologiche, neurodegenerative e infiammatorie basati su microRNA contenuto in microvescicole microglia
KR101904795B1 (ko) * 2015-12-17 2018-10-05 (주) 어드밴스드 엔티 기분 장애 정신 질환의 진단 또는 예후 분석을 위한 miRNA-206을 검출하는 방법, 진단을 위한 정보 제공 방법 및 miRNA-206을 표적으로 하는 조성물
IT201600093825A1 (it) * 2016-09-19 2018-03-19 Fondazione St Italiano Tecnologia Composizione farmaceutica di miRNA e suoi usi terapeutici.
KR20180063954A (ko) 2016-12-02 2018-06-14 서울대학교산학협력단 알츠하이머병 치료를 위한 마이크로RNA-188-5p의 용도
KR102177130B1 (ko) * 2017-08-18 2020-11-10 (주)큐라미스 근육 질환 및 신경근육 질환 예방, 치료 또는 진단을 위한 miR-18b의 용도
WO2019035690A1 (ko) * 2017-08-18 2019-02-21 서울대학교병원 근육 질환 및 신경근육 질환 예방, 치료 또는 진단을 위한 miR-18b의 용도
EP3710014A1 (en) 2017-11-14 2020-09-23 Henry Ford Health System Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
JP7414237B2 (ja) 2018-02-13 2024-01-16 東レ株式会社 認知症の検出のためのキット又はデバイス及び方法
US20210260002A1 (en) * 2018-06-18 2021-08-26 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
US20210292840A1 (en) * 2018-07-25 2021-09-23 Srnalytics, Inc. Small rna predictors for alzheimer's disease
JP2021534790A (ja) * 2018-08-30 2021-12-16 ネクスモス カンパニー リミテッドNexmos Co., Ltd. 血液脳関門を通過するアプタマー及びその応用
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA
US10844380B1 (en) 2019-06-17 2020-11-24 Biorchestra Co., Ltd. Uses for prevention or treatment of brain diseases using microrna
CN112280845A (zh) * 2020-09-22 2021-01-29 山东大学第二医院 miR-328-3p在制备脑梗死及脑缺血再灌注预后预测试剂中的应用
CN114438195A (zh) * 2022-02-28 2022-05-06 暨南大学 阿尔茨海默病检测试剂盒、存储介质及电子设备
CN114990159A (zh) * 2022-05-18 2022-09-02 昆明理工大学 一种micorRNA206抑制HCV增殖的建立方法
WO2024186630A1 (en) 2023-03-03 2024-09-12 Henry Ford Health System Use of extracellular vesicles for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279846A1 (en) * 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US20080313773A1 (en) * 2007-05-14 2008-12-18 The Rockefeller University Production of artificial micrornas using synthetic microrna precursors
US20090246136A1 (en) * 2008-03-17 2009-10-01 Andrew Williams Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100485819B1 (ko) * 2001-08-09 2005-04-28 삼성전자주식회사 디지털 데이터의 고속 전역 탐색 장치 및 방법
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
WO2007044937A2 (en) * 2005-10-13 2007-04-19 President And Fellows Of Harvard College Compositions and methods to modulate memory
CA2903764A1 (en) * 2005-12-12 2007-06-21 The University Of North Carolina At Chapel Hill Micrornas that regulate muscle cell proliferation and differentiation
US8415096B2 (en) * 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
WO2009026576A1 (en) * 2007-08-23 2009-02-26 Keren Pharmaceuticals Targeting rna with external guide sequences
WO2009091972A2 (en) * 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279846A1 (en) * 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US20080313773A1 (en) * 2007-05-14 2008-12-18 The Rockefeller University Production of artificial micrornas using synthetic microrna precursors
US20090246136A1 (en) * 2008-03-17 2009-10-01 Andrew Williams Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2617433A4 *

Also Published As

Publication number Publication date
JP2013542921A (ja) 2013-11-28
KR101235256B1 (ko) 2013-02-21
EP2617433A2 (en) 2013-07-24
WO2012036433A2 (ko) 2012-03-22
JP5710001B2 (ja) 2015-04-30
KR20120088009A (ko) 2012-08-08
CN103189069B (zh) 2017-06-06
US9301969B2 (en) 2016-04-05
EP2617433B1 (en) 2016-05-18
US20130184331A1 (en) 2013-07-18
EP2617433A4 (en) 2014-04-23
CN103189069A (zh) 2013-07-03

Similar Documents

Publication Publication Date Title
WO2012036433A3 (ko) miRNA를 타겟으로 한 신경퇴행성 질환 치료
MX2023006169A (es) Terapia genica para trastornos neurodegenerativos.
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2014022739A3 (en) Modified rnai agents
WO2010115843A3 (en) Pharmaceutical composition
WO2012045882A3 (en) Phosphospecific antibodies recognising tau
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
EA201270480A1 (ru) Новые соединения
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2010144721A3 (en) Model systems and treatment regimes for treatment of neurological disease
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2011131693A3 (en) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2010080452A3 (en) siRNA COMPOUNDS AND METHODS OF USE THEREOF
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201170190A1 (ru) Фармацевтическая композиция, содержащая экстракт мозга свиньи
WO2010064248A3 (en) Methods of diagnosing and treating motor neuron diseases
WO2009099642A3 (en) Proteomic analysis of active multiple sclerosis lesions
WO2008135661A3 (fr) Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines
WO2013052158A3 (en) Targeted nanovectors and their use for treatment of brain tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11825393

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013529052

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13822641

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011825393

Country of ref document: EP